Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study

Authors not listed

Vienna Institute for Research in Ocular Surgery · 2024

Abstract

This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual acuity.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2024). Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study. <em>Vienna Institute for Research in Ocular Surgery</em>. https://clinicaltrials.gov/study/NCT07390253
Vancouver
Anonymous. Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study. Vienna Institute for Research in Ocular Surgery. 2024.
BibTeX
@misc{anon2024Aflibe, title = {Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study}, author = {Anonymous}, journal = {Vienna Institute for Research in Ocular Surgery}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings